SCHEMBL2492280

SCHEMBL2492280

Oc1ccc(Cc2c[nH]c3ccccc23)cc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ GPR84 Q9NQS5 3/20 0.62
▸ MAPT P10636 2/20 0.62
▸ AHR P35869 2/20 0.62
▸ CYP3A4 P08684 2/20 0.62
▸ TDP1 Q9NUW8 1/20 0.62
▸ HTR6 P50406 2/20 0.62
▸ GABRP O00591 1/20 0.54
▸ GABRD O14764 1/20 0.54
▸ GABRA1 P14867 1/20 0.54
▸ GABRB1 P18505 1/20 0.54
▸ GABRG2 P18507 1/20 0.54
▸ GABRB3 P28472 1/20 0.54
▸ GABRA5 P31644 1/20 0.54
▸ GABRA3 P34903 1/20 0.54
▸ GABRA2 P47869 1/20 0.54
▸ GABRB2 P47870 1/20 0.54
▸ GABRA4 P48169 1/20 0.54
▸ GABRE P78334 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16431661 0.83 MEN1 (0.74) MEN1KMT2AGPR84MAPTAHR
SCHEMBL21399803 0.83 MEN1 (0.55) MEN1KMT2AGPR84MAPTAHR
SCHEMBL553605 0.79 MEN1 (1.00) MEN1KMT2AGPR84MAPTAHR
SCHEMBL30648199 0.79 MEN1 (1.00) MEN1KMT2AGPR84MAPTAHR
SCHEMBL27337415 0.79 KMT2A (0.69) MEN1KMT2AMAPTGABRPGABRD
Arundine SCHEMBL325162 0.78 MEN1 (1.00) MEN1KMT2AGPR84MAPTAHR
SCHEMBL31756934 0.78 MEN1 (0.61) MEN1KMT2AGPR84MAPTAHR
SCHEMBL28961243 0.78 MEN1 (0.61) MEN1KMT2AGPR84MAPTAHR
SCHEMBL5871352 0.77 MEN1 (0.74) MEN1KMT2AGPR84MAPTAHR
SCHEMBL5774387 0.77 MEN1 (0.74) MEN1KMT2AGPR84MAPTAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 — — WO claimed
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 — — US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
WO-2012079032-A2 COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS TRANA DISCOVERY, INC. (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885GPR84 4573/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885GPR84 4573/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885GPR84 4573/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MEN1 4495/4885KMT2A 2800/4885GPR84 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback